Trial Outcomes & Findings for Somatosensory Modulation of Salivary Gene Expression and Oral Feeding in Preterm Infants (NCT NCT02696343)
NCT ID: NCT02696343
Last Updated: 2026-02-27
Results Overview
RT PCR gene expression profiles for CDH13 (Cadherin 13, a protein Coding gene), FOXP2 (encodes a member of the forkhead/winged-helix (FOX) family of transcription factors), NPHP4 (Nephronophthisis 4), NPY2R (Neuropeptide Y2 receptor), PLXNA1 (involved in several processes, including generation of neurons; regulation of GTPase activity; and regulation of cell shape), and Wingless-type integration site family (WNT3). Data presented here represent the median values and interquartile range, combined across measurement timepoints. All genes were run on the RT-qPCR platform in duplicate. Normalized gene expression was calculated by the delta CT-method.
COMPLETED
NA
121 participants
Normalized gene expression data were obtained from a single salivary sample collected weekly from 30 wks (baseline) through 34 wks PMA when NTrainer intervention ceased. Phase1 samples collected 31-32 wks PMA; phase2 samples collected 33-34 wks PMA.
2026-02-27
Participant Flow
Participant milestones
| Measure |
NTrainer Non-BPD
Preterm infants non-BPD randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
NTrainer BPD
NTrainer BPD infants randomized to receive the PULSED orocutaneous stimulation through a pressurized green Soothie pacifier
|
Sham Non-BPD
Preterm infants non-BPD randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
Sham BPD
Preterm infants w/BPD randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
44
|
20
|
38
|
19
|
|
Overall Study
COMPLETED
|
42
|
19
|
35
|
18
|
|
Overall Study
NOT COMPLETED
|
2
|
1
|
3
|
1
|
Reasons for withdrawal
| Measure |
NTrainer Non-BPD
Preterm infants non-BPD randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
NTrainer BPD
NTrainer BPD infants randomized to receive the PULSED orocutaneous stimulation through a pressurized green Soothie pacifier
|
Sham Non-BPD
Preterm infants non-BPD randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
Sham BPD
Preterm infants w/BPD randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
|---|---|---|---|---|
|
Overall Study
Lost to Follow-up
|
2
|
1
|
3
|
1
|
Baseline Characteristics
difference due to newborn outbound transfers to a different hospital
Baseline characteristics by cohort
| Measure |
NTrainer Non-BPD
n=44 Participants
Preterm infants non-BPD randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation delivered through a pressurized regular green Soothie paired with tube feedings
|
NTrainer BPD
n=20 Participants
Preterm infants w/BPD randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation delivered through a pressurized regular green Soothie paired with tube feedings
|
Sham Non-BPD
n=38 Participants
Preterm infants non-BPD randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
Sham BPD
n=19 Participants
Preterm infants w/BPD randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
Total
n=121 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
42 Participants
n=42 Participants • difference due to newborn outbound transfers to a different hospital
|
19 Participants
n=19 Participants • difference due to newborn outbound transfers to a different hospital
|
35 Participants
n=35 Participants • difference due to newborn outbound transfers to a different hospital
|
18 Participants
n=18 Participants • difference due to newborn outbound transfers to a different hospital
|
114 Participants
n=114 Participants • difference due to newborn outbound transfers to a different hospital
|
|
Age, Categorical
Between 18 and 65 years
|
0 Participants
n=42 Participants • difference due to newborn outbound transfers to a different hospital
|
0 Participants
n=19 Participants • difference due to newborn outbound transfers to a different hospital
|
0 Participants
n=35 Participants • difference due to newborn outbound transfers to a different hospital
|
0 Participants
n=18 Participants • difference due to newborn outbound transfers to a different hospital
|
0 Participants
n=114 Participants • difference due to newborn outbound transfers to a different hospital
|
|
Age, Categorical
>=65 years
|
0 Participants
n=42 Participants • difference due to newborn outbound transfers to a different hospital
|
0 Participants
n=19 Participants • difference due to newborn outbound transfers to a different hospital
|
0 Participants
n=35 Participants • difference due to newborn outbound transfers to a different hospital
|
0 Participants
n=18 Participants • difference due to newborn outbound transfers to a different hospital
|
0 Participants
n=114 Participants • difference due to newborn outbound transfers to a different hospital
|
|
Age, Continuous
|
27.50 weeks
n=42 Participants • difference due to newborn outbound transfers to a different hospital
|
26.36 weeks
n=19 Participants • difference due to newborn outbound transfers to a different hospital
|
27.29 weeks
n=35 Participants • difference due to newborn outbound transfers to a different hospital
|
27.57 weeks
n=18 Participants • difference due to newborn outbound transfers to a different hospital
|
27.14 weeks
n=114 Participants • difference due to newborn outbound transfers to a different hospital
|
|
Sex: Female, Male
Female
|
18 Participants
n=42 Participants • difference due to newborn outbound transfers to a different hospital
|
10 Participants
n=19 Participants • difference due to newborn outbound transfers to a different hospital
|
21 Participants
n=35 Participants • difference due to newborn outbound transfers to a different hospital
|
7 Participants
n=18 Participants • difference due to newborn outbound transfers to a different hospital
|
56 Participants
n=114 Participants • difference due to newborn outbound transfers to a different hospital
|
|
Sex: Female, Male
Male
|
24 Participants
n=42 Participants • difference due to newborn outbound transfers to a different hospital
|
9 Participants
n=19 Participants • difference due to newborn outbound transfers to a different hospital
|
14 Participants
n=35 Participants • difference due to newborn outbound transfers to a different hospital
|
11 Participants
n=18 Participants • difference due to newborn outbound transfers to a different hospital
|
58 Participants
n=114 Participants • difference due to newborn outbound transfers to a different hospital
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
22 Participants
n=42 Participants • difference due to newborn outbound transfers to a different hospital
|
8 Participants
n=19 Participants • difference due to newborn outbound transfers to a different hospital
|
19 Participants
n=35 Participants • difference due to newborn outbound transfers to a different hospital
|
8 Participants
n=18 Participants • difference due to newborn outbound transfers to a different hospital
|
57 Participants
n=114 Participants • difference due to newborn outbound transfers to a different hospital
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
16 Participants
n=42 Participants • difference due to newborn outbound transfers to a different hospital
|
11 Participants
n=19 Participants • difference due to newborn outbound transfers to a different hospital
|
12 Participants
n=35 Participants • difference due to newborn outbound transfers to a different hospital
|
9 Participants
n=18 Participants • difference due to newborn outbound transfers to a different hospital
|
48 Participants
n=114 Participants • difference due to newborn outbound transfers to a different hospital
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
4 Participants
n=42 Participants • difference due to newborn outbound transfers to a different hospital
|
0 Participants
n=19 Participants • difference due to newborn outbound transfers to a different hospital
|
4 Participants
n=35 Participants • difference due to newborn outbound transfers to a different hospital
|
1 Participants
n=18 Participants • difference due to newborn outbound transfers to a different hospital
|
9 Participants
n=114 Participants • difference due to newborn outbound transfers to a different hospital
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=42 Participants • difference due to newborn outbound transfer to a different hospital
|
0 Participants
n=19 Participants • difference due to newborn outbound transfer to a different hospital
|
0 Participants
n=35 Participants • difference due to newborn outbound transfer to a different hospital
|
0 Participants
n=18 Participants • difference due to newborn outbound transfer to a different hospital
|
0 Participants
n=114 Participants • difference due to newborn outbound transfer to a different hospital
|
|
Race (NIH/OMB)
Asian
|
2 Participants
n=42 Participants • difference due to newborn outbound transfer to a different hospital
|
4 Participants
n=19 Participants • difference due to newborn outbound transfer to a different hospital
|
0 Participants
n=35 Participants • difference due to newborn outbound transfer to a different hospital
|
2 Participants
n=18 Participants • difference due to newborn outbound transfer to a different hospital
|
8 Participants
n=114 Participants • difference due to newborn outbound transfer to a different hospital
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=42 Participants • difference due to newborn outbound transfer to a different hospital
|
0 Participants
n=19 Participants • difference due to newborn outbound transfer to a different hospital
|
1 Participants
n=35 Participants • difference due to newborn outbound transfer to a different hospital
|
0 Participants
n=18 Participants • difference due to newborn outbound transfer to a different hospital
|
1 Participants
n=114 Participants • difference due to newborn outbound transfer to a different hospital
|
|
Race (NIH/OMB)
Black or African American
|
4 Participants
n=42 Participants • difference due to newborn outbound transfer to a different hospital
|
2 Participants
n=19 Participants • difference due to newborn outbound transfer to a different hospital
|
6 Participants
n=35 Participants • difference due to newborn outbound transfer to a different hospital
|
2 Participants
n=18 Participants • difference due to newborn outbound transfer to a different hospital
|
14 Participants
n=114 Participants • difference due to newborn outbound transfer to a different hospital
|
|
Race (NIH/OMB)
White
|
25 Participants
n=42 Participants • difference due to newborn outbound transfer to a different hospital
|
12 Participants
n=19 Participants • difference due to newborn outbound transfer to a different hospital
|
21 Participants
n=35 Participants • difference due to newborn outbound transfer to a different hospital
|
13 Participants
n=18 Participants • difference due to newborn outbound transfer to a different hospital
|
71 Participants
n=114 Participants • difference due to newborn outbound transfer to a different hospital
|
|
Race (NIH/OMB)
More than one race
|
2 Participants
n=42 Participants • difference due to newborn outbound transfer to a different hospital
|
0 Participants
n=19 Participants • difference due to newborn outbound transfer to a different hospital
|
1 Participants
n=35 Participants • difference due to newborn outbound transfer to a different hospital
|
0 Participants
n=18 Participants • difference due to newborn outbound transfer to a different hospital
|
3 Participants
n=114 Participants • difference due to newborn outbound transfer to a different hospital
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
9 Participants
n=42 Participants • difference due to newborn outbound transfer to a different hospital
|
1 Participants
n=19 Participants • difference due to newborn outbound transfer to a different hospital
|
6 Participants
n=35 Participants • difference due to newborn outbound transfer to a different hospital
|
1 Participants
n=18 Participants • difference due to newborn outbound transfer to a different hospital
|
17 Participants
n=114 Participants • difference due to newborn outbound transfer to a different hospital
|
|
Region of Enrollment
United States
|
42 participants
n=42 Participants • difference due to newborn outbound transfer to a different hospital
|
19 participants
n=19 Participants • difference due to newborn outbound transfer to a different hospital
|
35 participants
n=35 Participants • difference due to newborn outbound transfer to a different hospital
|
18 participants
n=18 Participants • difference due to newborn outbound transfer to a different hospital
|
114 participants
n=114 Participants • difference due to newborn outbound transfer to a different hospital
|
PRIMARY outcome
Timeframe: Normalized gene expression data were obtained from a single salivary sample collected weekly from 30 wks (baseline) through 34 wks PMA when NTrainer intervention ceased. Phase1 samples collected 31-32 wks PMA; phase2 samples collected 33-34 wks PMA.Population: Preterm infants (non-BPD, BPD) who provided 2 salivary samples per week.
RT PCR gene expression profiles for CDH13 (Cadherin 13, a protein Coding gene), FOXP2 (encodes a member of the forkhead/winged-helix (FOX) family of transcription factors), NPHP4 (Nephronophthisis 4), NPY2R (Neuropeptide Y2 receptor), PLXNA1 (involved in several processes, including generation of neurons; regulation of GTPase activity; and regulation of cell shape), and Wingless-type integration site family (WNT3). Data presented here represent the median values and interquartile range, combined across measurement timepoints. All genes were run on the RT-qPCR platform in duplicate. Normalized gene expression was calculated by the delta CT-method.
Outcome measures
| Measure |
Sham Non-BPD
n=24 Participants
Preterm infants (non-BPD) randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
Sham BPD
n=17 Participants
Preterm infants (BPD) randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
NTrainer Non-BPD
n=32 Participants
Preterm infants (non-BPD) randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
NTrainer BPD
n=19 Participants
Preterm infants (BPD) randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
|---|---|---|---|---|
|
Salivary Gene Expression
CDH13 gene
|
20.931 Delta-CT
Interval 16.505 to 23.776
|
21.100 Delta-CT
Interval 16.75 to 23.83
|
21.344 Delta-CT
Interval 15.941 to 23.847
|
21.420 Delta-CT
Interval 14.938 to 24.881
|
|
Salivary Gene Expression
NPY2R gene
|
9.215 Delta-CT
Interval 4.688 to 12.835
|
7.527 Delta-CT
Interval 3.836 to 13.097
|
9.201 Delta-CT
Interval 5.691 to 12.976
|
7.468 Delta-CT
Interval 4.211 to 11.811
|
|
Salivary Gene Expression
FOXP2 gene
|
12.499 Delta-CT
Interval 10.892 to 17.819
|
12.181 Delta-CT
Interval 10.466 to 18.801
|
11.879 Delta-CT
Interval 10.513 to 17.017
|
11.844 Delta-CT
Interval 10.593 to 14.546
|
|
Salivary Gene Expression
NPHP4 gene
|
12.479 Delta-CT
Interval 10.409 to 18.283
|
11.158 Delta-CT
Interval 9.759 to 15.527
|
11.721 Delta-CT
Interval 10.18 to 14.628
|
11.776 Delta-CT
Interval 10.168 to 14.781
|
|
Salivary Gene Expression
PLXNA1 gene
|
9.338 Delta-CT
Interval 7.892 to 12.568
|
8.746 Delta-CT
Interval 7.573 to 10.949
|
8.728 Delta-CT
Interval 7.805 to 10.663
|
9.136 Delta-CT
Interval 7.659 to 12.065
|
|
Salivary Gene Expression
WNT3 gene
|
20.083 Delta-CT
Interval 15.537 to 23.392
|
20.632 Delta-CT
Interval 15.457 to 23.646
|
20.674 Delta-CT
Interval 14.264 to 23.265
|
19.791 Delta-CT
Interval 14.394 to 23.915
|
SECONDARY outcome
Timeframe: Mixed modeling (LMM) repeated measures used to analyze NNS Bursts/min. Means and S.E. reported in the Measure Description were derived from LMM. The Mean represents overall average of the NNS Bursts/min across multiple time points, (adj. GA, PMA, Sex).NNS Bursts/min was calculated from a 2-minute digitized suck compression record sampled at 3-day intervals/week beginning a 30 weeks PMA. NNS Bursts/min represent the means and standard errors estimated by linear mixed modeling of all data samples collected for study infants over this time period.
Outcome measures
| Measure |
Sham Non-BPD
n=35 Participants
Preterm infants (non-BPD) randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
Sham BPD
n=18 Participants
Preterm infants (BPD) randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
NTrainer Non-BPD
n=42 Participants
Preterm infants (non-BPD) randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
NTrainer BPD
n=19 Participants
Preterm infants (BPD) randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
|---|---|---|---|---|
|
NNS Bursts/Minute
|
5.71 NNS Bursts/min
Standard Error 0.30
|
5.21 NNS Bursts/min
Standard Error 0.40
|
5.72 NNS Bursts/min
Standard Error 0.40
|
5.98 NNS Bursts/min
Standard Error 0.39
|
SECONDARY outcome
Timeframe: Time expressed in days for an infant to attain full oral feed (100% PO), assessed on a daily basis beginning at 30 weeks PMA through their stay in the NICU, for an average of fifty-six %PO measures sampled over 8 weeks.Daily records of feeding modes (tube feed vs oral feed) and proportion of nutrient taken orally (%PO) were used to model the growth to independent Full Oral Feeds. The means and standard errors for %PO were estimated by linear mixed modeling of all data samples collected for study infants over this time period.
Outcome measures
| Measure |
Sham Non-BPD
n=35 Participants
Preterm infants (non-BPD) randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
Sham BPD
n=18 Participants
Preterm infants (BPD) randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
NTrainer Non-BPD
n=42 Participants
Preterm infants (non-BPD) randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
NTrainer BPD
n=19 Participants
Preterm infants (BPD) randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
|---|---|---|---|---|
|
Time-to-transition to Full Oral Feed
|
15.24 %PO
Standard Error 1.92
|
7.13 %PO
Standard Error 2.54
|
17.40 %PO
Standard Error 1.74
|
12.79 %PO
Standard Error 2.43
|
SECONDARY outcome
Timeframe: Mixed modeling (LMM) repeated measures used to analyze NNS Cycles/min. Means and S.E. reported in the Measure Description were derived from LMM. The Mean represents overall average of the NNS Cycles/min across multiple time points, (adj. GA, PMA, Sex).Automatic algorithm (NeoNNS.exe) applied to perform non-nutritive suck compression dynamics waveform discrimination to calculate the number of NNS Cycles/min. NNS Cycles/min was calculated from a 2-minute digitized suck compression waveform record sampled at 3-day intervals/week beginning a 30 weeks PMA. NNS Bursts/min represent the means and standard errors estimated by linear mixed modeling of all data samples collected for study infants over this time period.
Outcome measures
| Measure |
Sham Non-BPD
n=35 Participants
Preterm infants (non-BPD) randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
Sham BPD
n=18 Participants
Preterm infants (BPD) randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
NTrainer Non-BPD
n=42 Participants
Preterm infants (non-BPD) randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
NTrainer BPD
n=19 Participants
Preterm infants (BPD) randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
|---|---|---|---|---|
|
NNS Cycles/Min
|
55.89 NNS cycles/min
Standard Error 4.25
|
50.30 NNS cycles/min
Standard Error 5.78
|
54.56 NNS cycles/min
Standard Error 3.86
|
53.70 NNS cycles/min
Standard Error 5.54
|
SECONDARY outcome
Timeframe: Mixed modeling (LMM) repeated measures used to analyze NNS STI. Means and S.E. reported in the Measure Description were derived from LMM. The Mean represents overall average of the NNS STI across multiple time points, (adj. GA, PMA, Sex).Automated waveform discrimination (NeoNNS.exe) was used to calculate Non-nutritive Suck SpatioTemporal Index (NNS STI) based on the first 5 suck compression cycles for 5 NNS bursts. The NNS STI was calculated from a 2-minute digitized suck compression waveform record sampled at 3-day intervals/week beginning a 30-weeks PMA. The NNS STI represents the means and standard errors estimated by linear mixed modeling of all data samples collected for study infants over this time period. The range of NNS Spatiotemporal index scores falls between 100 and 20. Higher NNS STI scores mean a worse outcome, whereas lower NNS STI scores mean a better outcome.
Outcome measures
| Measure |
Sham Non-BPD
n=35 Participants
Preterm infants (non-BPD) randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
Sham BPD
n=18 Participants
Preterm infants (BPD) randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
NTrainer Non-BPD
n=42 Participants
Preterm infants (non-BPD) randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
NTrainer BPD
n=19 Participants
Preterm infants (BPD) randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
|---|---|---|---|---|
|
Non-nutritive Suck Spatiotemporal Index (NNS STI)
|
65.97 score on a scale
Standard Error 2.67
|
67.62 score on a scale
Standard Error 3.65
|
63.84 score on a scale
Standard Error 2.43
|
65.16 score on a scale
Standard Error 3.50
|
SECONDARY outcome
Timeframe: Beginning at 30 weeks PMA, we completed repeated sampling and calculation of non-nutritive suck compression amplitude (cm H2O) from a 2-min digitized sample 3 times per week during the infant's stay in the NICU.Automatic algorithm (NeoNNS.exe) applied to perform non-nutritive suck compression dynamics waveform discrimination to calculate the NNS compression amplitude (cmH2O). This dependent measure was calculated from a 2-minute digitized suck compression waveform record sampled at 3-day intervals/week beginning at 30-weeks PMA. Non-nutritive suck compression amplitude represents the means and standard errors estimated by linear mixed modeling of all data samples collected for study infants over this time period.
Outcome measures
| Measure |
Sham Non-BPD
n=35 Participants
Preterm infants (non-BPD) randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
Sham BPD
n=18 Participants
Preterm infants (BPD) randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
NTrainer Non-BPD
n=42 Participants
Preterm infants (non-BPD) randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
NTrainer BPD
n=19 Participants
Preterm infants (BPD) randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
|---|---|---|---|---|
|
Non-nutritive Suck Compression Amplitude (cmH2O)
|
29.03 cmH2O
Standard Error 2.67
|
22.68 cmH2O
Standard Error 3.65
|
28.41 cmH2O
Standard Error 2.43
|
27.87 cmH2O
Standard Error 3.50
|
SECONDARY outcome
Timeframe: 18 months corrected age (CA)Physical Growth and Feeding progression, and the mode of feeding following NICU discharge up to 18 months. The response rate for the NICHD Neonatal Research Network feed-growth questionnaire was 73/121 (60.33%). This low response rate corresponds to the height of the COVID-19 pandemic. Bivariate tests were performed to compare SHAM and NTrainer groups -- independent-samples t-test for continuous variables and chi-square test for categorical variables.
Outcome measures
| Measure |
Sham Non-BPD
n=25 Participants
Preterm infants (non-BPD) randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
Sham BPD
n=11 Participants
Preterm infants (BPD) randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
NTrainer Non-BPD
n=21 Participants
Preterm infants (non-BPD) randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
NTrainer BPD
n=16 Participants
Preterm infants (BPD) randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
|---|---|---|---|---|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q3. Has child had 1 or more seizures since discharge? [Yes]
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q2c2. Anticonvulsants/seizure meds [Yes, but stopped]
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q2c3. Anticonvulsants/seizure meds [Yes, still using]
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q2e1. Muscle relaxants and/or antispasticity meds? [No]
|
8 Participants
|
6 Participants
|
4 Participants
|
3 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q4. Has child been diagnosed with Autism Spectrum Disorder? [Yes]
|
2 Participants
|
0 Participants
|
2 Participants
|
3 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q5a. Apnea monitor? [Yes]
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q6a. Oral Motor Skills-independent? [Yes]
|
17 Participants
|
8 Participants
|
18 Participants
|
9 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q6b. Oral Motor Skills-dependent oral feed, all p.o. [Yes]
|
7 Participants
|
3 Participants
|
3 Participants
|
6 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q6c. Oral Motor Skills-limited oral feeding [Yes]
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q6d. Oral Motor Skills-No oral feeding [Yes]
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q7a. Resists/refuses some/all food by mouth (oral aversion)? [Yes]
|
3 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q9b. Thickened liquids? [Yes]
|
19 Participants
|
10 Participants
|
12 Participants
|
12 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q10b. Braces/orthotics? [Yes]
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q10c. Walker? [Yes]
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q10d. Stander? [Yes]
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q9c. Soft solids (baby food, pureed food)? [Yes]
|
21 Participants
|
10 Participants
|
11 Participants
|
13 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q1. Has child been rehospitalized since discharge to home or chronic care facility? [Yes]
|
11 Participants
|
5 Participants
|
8 Participants
|
3 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q2. Has child taken any meds repeatedly in the last 3 months? [Yes]
|
8 Participants
|
6 Participants
|
4 Participants
|
3 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q2a1. Anti-reflux meds? [No]
|
6 Participants
|
4 Participants
|
3 Participants
|
2 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q2a2. Anti-reflux meds? [Yes, but stopped]
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q2a3. Anti-reflux meds [Yes, still using]
|
1 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q2b1. Asthma/BPD meds? [No}
|
1 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q2b2. Asthma/BPD meds? [Yes, but stopped]
|
2 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q2b3. Asthma/BPD meds? [Yes, still using]
|
5 Participants
|
5 Participants
|
4 Participants
|
2 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q2c1. Anticonvulsants/seizure meds? [No]
|
8 Participants
|
6 Participants
|
4 Participants
|
3 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q2d1. Thyroid meds? [No]
|
8 Participants
|
6 Participants
|
4 Participants
|
3 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q2d2. Thyroid meds? [Yes, but stopped]
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q2d3. Thyroid meds? [Yes, still using]
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q2e2. Muscle relaxants and/or antispasticity meds? [Yes, but stopped]
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q2e3. Muscle relaxants and/or antispasticity meds? [Yes, still using]
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q5b. Oxygen? [Yes]
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q5c. Vent/CPAP? [Yes]
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q5d. Gastrostomy tube/tube feeds? [Yes]
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q5e. Tracheostomy? [Yes]
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q5f. Pulse oximetry? [Yes]
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q7b. Difficulty swallowing food (mouth/throat/dysphagia)? [Yes]
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q9d. Table food (req chewing)? [Yes]
|
24 Participants
|
11 Participants
|
20 Participants
|
14 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q10. Does your child use any of the following equipment/or has any been ordered? [Yes]
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q10a. Adapted stroller/wheelchair? [Yes]
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q7c. Documented aspiration (food down windpipe)? [Yes]
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q8. High calorie oral supplements? [Yes]
|
1 Participants
|
2 Participants
|
2 Participants
|
4 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q10e. Corner chairs or tumbler form? [Yes]
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q9a. Thin liquids? [Yes]
|
19 Participants
|
10 Participants
|
13 Participants
|
14 Participants
|
|
National Institute Child Human Development (NICHD) Neonatal Research Network Feed-growth Questionnaire
Q11. Has child had any operations since discharge to home or chronic care facility? [Yes]
|
4 Participants
|
5 Participants
|
8 Participants
|
6 Participants
|
SECONDARY outcome
Timeframe: 24 months corrected age (CA)Population: Cognition subtest
The Bayley III neurodevelopmental Cognition subtest scoring scale is used to assess cognitive development in infants and toddlers. The scoring is based on norm-referenced values. A mean score of 100 represents average function. Scores below 85 suggest mild impairment, and scores below 70 indicate moderate-to-severe impairment. Percentile scores range from 0-100.
Outcome measures
| Measure |
Sham Non-BPD
n=17 Participants
Preterm infants (non-BPD) randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
Sham BPD
n=11 Participants
Preterm infants (BPD) randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
NTrainer Non-BPD
n=26 Participants
Preterm infants (non-BPD) randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
NTrainer BPD
n=16 Participants
Preterm infants (BPD) randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
|---|---|---|---|---|
|
Bayley III Developmental Scales-Cognition
|
88.06 score on a scale
Standard Error 3.25
|
86.23 score on a scale
Standard Error 4.07
|
91.53 score on a scale
Standard Error 2.61
|
91.41 score on a scale
Standard Error 3.32
|
SECONDARY outcome
Timeframe: 24 months corrected age (CA)Population: Language subtest
Bayley III neurodevelopmental Language subtest is part of the Bayley Scales of Infant and Toddler Development, designed to assess language skills in young children. The scoring scale is based on norm-referenced values with a mean of 100 and a standard deviation of 15. A score below 85 suggests mild impairment, indicating that the child is "at risk" for developmental delay, while scores below 70 indicate significant developmental delay. The Bayley-III assesses language through subtests that evaluate receptive and expressive language skills, providing a comprehensive evaluation of a child's language development. Percentile scores range from 0-100.
Outcome measures
| Measure |
Sham Non-BPD
n=17 Participants
Preterm infants (non-BPD) randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
Sham BPD
n=11 Participants
Preterm infants (BPD) randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
NTrainer Non-BPD
n=26 Participants
Preterm infants (non-BPD) randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
NTrainer BPD
n=16 Participants
Preterm infants (BPD) randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
|---|---|---|---|---|
|
Bayley III Developmental Scales-Language
|
83.73 score on a scale
Standard Error 3.46
|
85.50 score on a scale
Standard Error 4.82
|
86.22 score on a scale
Standard Error 2.77
|
88.95 score on a scale
Standard Error 3.64
|
SECONDARY outcome
Timeframe: 24 months corrected age (CA)Population: Motor subtest
Bayley III neurodevelopmental Motor subtest is a norm-referenced scoring scale which is used to evaluate motor skills in infants and toddlers. The motor scale includes both fine and gross motor subtests, designed to assess skills such as prehension, motor planning, and coordination. A score of 100 represents average function. A score below 85 suggests mild impairment, indicating that the child is "at risk" for developmental delay. Scores below 70 indicate significant developmental delay. Percentile scores range from 0-100.
Outcome measures
| Measure |
Sham Non-BPD
n=17 Participants
Preterm infants (non-BPD) randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
Sham BPD
n=11 Participants
Preterm infants (BPD) randomized to receive the Sham (blind pacifier) during tube feedings.
SHAM blind pacifier: regular green Soothie pacifier paired with tube feedings
|
NTrainer Non-BPD
n=26 Participants
Preterm infants (non-BPD) randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
NTrainer BPD
n=16 Participants
Preterm infants (BPD) randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
NTrainer: pulsed orocutaneous stimulation paired with tube feedings
|
|---|---|---|---|---|
|
Bayley III Developmental Scales-Motor
|
89.89 score on a scale
Standard Error 2.99
|
85.30 score on a scale
Standard Error 3.74
|
90.95 score on a scale
Standard Error 2.40
|
96.41 score on a scale
Standard Error 3.06
|
Adverse Events
EPI Experimental
EPI Control
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place